Strong Jodi, Kruger Davida, Novak Lucia
a Ministry Medical Group , Stevens Point , WI , USA.
b Henry Ford Medical Center, Division of Endocrinology, Diabetes, Bone and Mineral Disorders , Detroit , MI , USA.
Curr Med Res Opin. 2017 Apr;33(4):785-793. doi: 10.1080/03007995.2017.1288614. Epub 2017 Mar 7.
Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Glucose control: Recently approved in the United States and in Europe for use in type 1 and type 2 diabetes, Gla-300 has a more constant and evenly distributed glucose-lowering effect compared with Gla-100, with a duration of action beyond 24 hours and lower within-day and between-day intra-individual variability in blood glucose levels. These benefits translate into predictable and sustained glucose control from a once-daily injection, with potential for fewer hypoglycemia episodes and less weight gain.
Case studies are presented to highlight the potential clinical benefits and considerations associated with initiating treatment with Gla-300 in people with type 1 and type 2 diabetes.
甘精胰岛素300单位/毫升:甘精胰岛素300单位/毫升(Gla-300)是甘精胰岛素的一种制剂,其在三分之一的甘精胰岛素100单位/毫升(Gla-100)注射体积中输送相同数量的胰岛素单位。血糖控制:Gla-300最近在美国和欧洲被批准用于1型和2型糖尿病,与Gla-100相比,它具有更持续且分布更均匀的降糖效果,作用持续时间超过24小时,日内和日间个体内血糖水平变异性更低。这些益处转化为每日一次注射可实现可预测且持续的血糖控制,低血糖发作次数可能更少且体重增加更少。
呈现病例研究以突出在1型和2型糖尿病患者中起始使用Gla-300治疗相关的潜在临床益处和注意事项。